Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | 09/30/2025 | 09/30/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -551.14% | 58.91% | -771.05% | -771.05% | -771.05% |
| Total Depreciation and Amortization | -4.17% | 8.87% | 3.50% | 3.50% | 3.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 291.50% | -16.05% | 62.93% | 62.93% | 62.93% |
| Change in Net Operating Assets | 164.95% | -255.69% | 162.18% | 162.18% | 162.18% |
| Cash from Operations | 417.31% | -146.57% | -67.05% | -67.05% | -67.05% |
| Capital Expenditure | -77.78% | 54.11% | 17.17% | 17.17% | 17.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -77.78% | 54.11% | 17.17% | 17.17% | 17.17% |
| Total Debt Issued | 30.00% | -23.08% | -90.59% | -90.59% | -90.59% |
| Total Debt Repaid | -30.00% | 23.08% | 90.36% | 90.36% | 90.36% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 99.84% | -- | -576.02% | -576.02% | -576.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -0.42% | 7.03% | -- | -- | -- |
| Cash from Financing | 71.83% | -232.81% | -245.27% | -245.27% | -245.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 263.03% | -206.86% | -147.86% | -147.86% | -147.86% |